SEC Form 4 · accession 0001209191-18-015835
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Jolly
Officer — EVP, Research & Pharm Devel
Period of report
Mar 1, 2018
Accepted (ET)
Mar 2, 2018 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $11.19 | Mar 1, 2018 | A | 25,000 | A | — | Feb 29, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F11/4th of the shares vest one year after 3/01/2018; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 3/01/2018.